These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24307741)

  • 1. The survival benefits of antiretroviral therapy in South Africa.
    April MD; Wood R; Berkowitz BK; Paltiel AD; Anglaret X; Losina E; Freedberg KA; Walensky RP
    J Infect Dis; 2014 Feb; 209(4):491-9. PubMed ID: 24307741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
    Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
    AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.
    Luz PM; Girouard MP; Grinsztejn B; Freedberg KA; Veloso VG; Losina E; Struchiner CJ; MacLean RL; Parker RA; Paltiel AD; Walensky RP
    J Int AIDS Soc; 2016; 19(1):20623. PubMed ID: 27029828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.
    Cornell M; Johnson LF; Wood R; Tanser F; Fox MP; Prozesky H; Schomaker M; Egger M; Davies MA; Boulle A;
    J Int AIDS Soc; 2017 Sep; 20(1):21902. PubMed ID: 28953328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
    Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
    Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
    Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L;
    PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean.
    Wolf LL; Ricketts P; Freedberg KA; Williams-Roberts H; Hirschhorn LR; Allen-Ferdinand K; Rodriguez WR; Divi N; Wong MT; Losina E
    J Acquir Immune Defic Syndr; 2007 Dec; 46(4):463-71. PubMed ID: 18077836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa.
    Osler M; Hilderbrand K; Goemaere E; Ford N; Smith M; Meintjes G; Kruger J; Govender NP; Boulle A
    Clin Infect Dis; 2018 Mar; 66(suppl_2):S118-S125. PubMed ID: 29514233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study.
    Johnson LF; May MT; Dorrington RE; Cornell M; Boulle A; Egger M; Davies MA
    PLoS Med; 2017 Dec; 14(12):e1002468. PubMed ID: 29232366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
    Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
    AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa.
    Eaton JW; Johnson LF; Salomon JA; Bärnighausen T; Bendavid E; Bershteyn A; Bloom DE; Cambiano V; Fraser C; Hontelez JA; Humair S; Klein DJ; Long EF; Phillips AN; Pretorius C; Stover J; Wenger EA; Williams BG; Hallett TB
    PLoS Med; 2012; 9(7):e1001245. PubMed ID: 22802730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.
    Olney JJ; Braitstein P; Eaton JW; Sang E; Nyambura M; Kimaiyo S; McRobie E; Hogan JW; Hallett TB
    Lancet HIV; 2016 Dec; 3(12):e592-e600. PubMed ID: 27771231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
    Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA
    N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.
    Siedner MJ; Ng CK; Bassett IV; Katz IT; Bangsberg DR; Tsai AC
    Clin Infect Dis; 2015 Apr; 60(7):1120-7. PubMed ID: 25516189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.